Syndax price target raised to $43 from $35 at BTIG

BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having announced FDA approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients, which comes 6-weeks earlier than the December 26 PDUFA date, the analyst tells investors in a research note. The label is fairly consistent with expectations on safety and efficacy, and BTIG does not see the recommendation for QTc monitoring initially with treatment as burdensome, the firm added.